ATOS

ATOS

USD

Atossa Therapeutics Inc. Common Stock

$0.855+0.012 (1.471%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$0.843

最高

$0.900

最低

$0.843

交易量

0.03M

公司基本面

市值

110.5M

行業

生物科技

國家

United States

交易統計

平均交易量

0.63M

交易所

NCM

貨幣

USD

52週範圍

最低 $0.55當前 $0.855最高 $1.81

相關新聞

GlobeNewswire

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

查看更多
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewswire

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

查看更多
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewswire

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

查看更多
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Analyst Upgrades

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics with a Buy and raises the price target from $7 to $7.25.

查看更多
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25